A Randomised Open-label Study to Compare the Effectiveness of the Fixed Dose Combination of FF/UMEC/VI (Using the Connected Inhaler System) With the Combination of FP/SAL Plus Tiotropium (Without the Connected Inhaler System) in Participants With Inadequately Controlled Asthma

Next Previous
Trial Profile

A Randomised Open-label Study to Compare the Effectiveness of the Fixed Dose Combination of FF/UMEC/VI (Using the Connected Inhaler System) With the Combination of FP/SAL Plus Tiotropium (Without the Connected Inhaler System) in Participants With Inadequately Controlled Asthma

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Feb 2018

At a glance

  • Drugs Fluticasone furoate/umeclidinium/vilanterol (Primary) ; Salmeterol/fluticasone propionate; Tiotropium bromide
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline

    • Most Recent Events

    • 09 Feb 2018 Planned End Date changed from 11 Sep 2020 to 18 Jan 2021.
    • 09 Feb 2018 Planned primary completion date changed from 11 Sep 2020 to 18 Jan 2021.
    • 09 Feb 2018 Planned initiation date changed from 27 Feb 2018 to 27 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top